Incyte (INCY) Financial Analysis & Valuation | Quarter Chart

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growt... more
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commerci... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$23.42BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEOWilliam J. Meury
IPO Date1993-11-04CAGR35.62%
Employees2,844Websitewww.incyte.com
Div. Yield—Payout Ratio—
Buy Back Yield0.02%Total Yield0.02%
INCY chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
Enterprise Value$19.35BP/E Ratio15.76
Forward P/E13.44PEG Ratio0.2
P/S Ratio60.93P/B Ratio58.67
P/CF Ratio214.66P/FCF Ratio224.99
EPS$7.44EPS Growth 1Y2112.5%
EPS Growth 3Y389.56%EPS Growth 5Y226.19%
Revenue Growth 1Y21.48%Gross Margin0.92%
Operating Margin0.27%Profit Margin0.27%
ROE0.29%ROA0.2%
ROCE0.25%Current Ratio3.68
Quick Ratio3.6Cash Ratio2.32
Debt/Equity0.01Interest Coverage620.56
Altman Z Score10.15Piotroski Score5

View Incyte financial charts →

Incyte (INCY) valuation & financials

Incyte (INCY) has a market capitalization of $23.42B and trades at a price-to-earnings ratio of 15.8. It operates in the Healthcare sector (Biotechnology).

Incyte's revenue grew +21.5% over the last year.

Incyte's next earnings report is scheduled for July 28, 2026 before market open; analysts estimate EPS of $1.97.

📈 Analysts estimate INCY EPS of $1.97 for the upcoming quarter. See Incyte revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Incyte (INCY) — frequently asked questions

When does Incyte (INCY) report earnings next?

Incyte is expected to report earnings on July 28, 2026 before market open. Analysts estimate EPS of $1.97.

What is Incyte's market cap?

Incyte (INCY) has a market capitalization of $23.42B.

What is INCY's P/E ratio?

Incyte trades at a price-to-earnings ratio of 15.8, with trailing twelve-month EPS of $7.44.

How fast is Incyte growing?

Incyte's revenue grew +21.5% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Merck (MRK)

Incyte revenue & earnings charts →